Van Herk Investments sent a letter to the Board of ProQR Therapeutics (PRQR)

Market Cap: $179 million| ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines.                                                                                

On May 23, 2025, Van Herk Investments (10.9%) sent a letter to the Board expressing strong opposition to the proposed reappointments of CEO Daniel de Boer and Chairman James Shannon at the June 2025 AGM. VHI cites repeated strategic failures, underperformance, and lack of board renewal, attributing poor oversight and entrenched leadership dynamics as root causes. VHI urges the Board to withdraw the reappointment proposals and initiate leadership changes to unlock the company’s potential, warning that failure to act may prompt further steps.

On August 19, 2025, Van Herk Investments (11.6%) criticized the Board for poor governance, citing Shannon’s extended tenure, entrenched directors, repeated failed strategies, and unjustified bonuses. It demands confirmation that Shannon and De Boer serve only until the 2026 AGM, a clear rationale for De Boer’s reappointment, a board rotation plan, and strict governance compliance, warning of legal action if ignored. Source